From a prepandemic to early-pandemic epoch, there was a decrease in the amount of unique patients who underwent imaging for the evaluation of stroke.
Among patients with COVID-19 pneumonia in the ICU with neurological symptoms, 44 percent of those undergoing MRI have acute findings.
Data from 103 patients diagnosed with COVID-19 indicated olfactory dysfunction occurs commonly, severely, and early in COVID-19 infection.
The ENSG-WFN published a report that details current understanding of the neurologic impacts of COVID-19.
Satralizumab monotherapy may reduce the risk for neuromyelitis optics spectrum disorder relapse, and has a favorable safety profile.
Pulmonary infiltrates and/or pleural effusion on chest radiograph may increase risk for admission.
A patient with a history of pulmonary paracoccidioidomycosis presented with relapsed disease in the central nervous system four years after initial treatment.
Five patients at 3 hospitals in northern Italy developed Guillain–Barré syndrome after the onset of coronavirus disease 2019 (COVID-19).
Mildly symptomatic patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often have alterations in smell or taste.
Acute respiratory distress syndrome (ARDS) due to COVID-19 is associated with neurologic features, including encephalopathy, agitation, and confusion